Lexicon Pharmaceuticals, Inc. (LXRX) Financial Statements
Lexicon Pharmaceuticals, Inc. (LXRX) reported trailing twelve-month revenue of $41.5M (down 29.0% year on year) and net income of -$61.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$65.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LXRXLexicon Pharmaceuticals, Inc.Follow LXRX — free
—
Price chart with a free account
- Market cap
- 631.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.8 | 1.1 | 2.2 | 22.9 | 130.0 | 79.3 | 91.7 | 63.2 | 322.1 | 24.0 | 0.3 | 0.1 | 1.2 | 31.1 | 49.8 | 41.5 | |
| Gross profit | — | — | — | — | — | — | 89.8 | 60.7 | 318.8 | 22.1 | 0.3 | 0.1 | 1.1 | 30.5 | 49.5 | — | |
| Research & development | 91.8 | 82.6 | 89.7 | 89.3 | 95.2 | 164.0 | 152.2 | 100.2 | 91.9 | 153.6 | 55.0 | 52.8 | 58.9 | 84.5 | 61.1 | 60.3 | |
| Operating income | -114.1 | -108.4 | -102.4 | -100.4 | 1.5 | -127.2 | -130.6 | -103.3 | 141.4 | -47.8 | -87.1 | -100.8 | -171.8 | -197.1 | -48.9 | -54.5 | |
| Pre-tax income | -116.2 | -110.2 | -104.1 | -100.4 | -4.7 | -131.4 | -135.7 | -120.5 | 124.1 | -58.6 | -87.8 | -101.9 | -177.1 | -200.4 | -50.3 | -61.1 | |
| Income tax | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | |
| Net income | -116.2 | -110.2 | -104.1 | -100.3 | -4.7 | -131.4 | -123.0 | -120.5 | 130.1 | -58.6 | -87.8 | -101.9 | -177.1 | -200.4 | -50.3 | -61.1 | |
| Diluted EPS ($) | -0.34 | -0.23 | -1.42 | -1.31 | -0.05 | -1.27 | -1.17 | -1.14 | — | -0.53 | -0.60 | -0.62 | -0.80 | -0.63 | -0.14 | -0.14 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | 110.8 | 145.7 | 165.7 | 221.1 | 320.0 | 363.1 | — |
USD millions · SEC XBRL
Lexicon Pharmaceuticals, Inc. — questions
- What is Lexicon Pharmaceuticals, Inc.'s revenue?
- $41.5M over the twelve months to 2026-06-30, down 29.0% year on year, from its 10-Q and 10-K filings.
- What is Lexicon Pharmaceuticals, Inc.'s net income?
- -$61.1M over the twelve months to 2026-06-30.
- What is Lexicon Pharmaceuticals, Inc.'s free cash flow?
- -$65.0M over the twelve months to 2026-06-30.
- What are Lexicon Pharmaceuticals, Inc.'s diluted earnings per share?
- $-0.14 over the twelve months to 2026-06-30.
Every figure on this page comes from Lexicon Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.